The effects of Ziziphus Spina leaves’ Hydro-Alcoholic Extract Vaginal Cream and Clotrimazole on Candida albicans in Wistar Rats

Azam Honarmandpour1, Mahnaz Fatahinia2, Amir Masoud Keshavarzzade3, Forogh Namjoyan4, Elham Maraghi5 and Hossein Kamali6

1Department of Midwifery, Shoushtar Faculty of Medical Sciences, Shoushtar, Iran. 2Department of Medical Mycology, Infectious and Tropical Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 3Young Researcher, Shoushtar School of Talaidaran of Exceptional Talents, Shoushtar, Iran. 4Pharmacognosy Department, Marine natural Pharmaceutical Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 5Department of Biostatistics and Epidemiology Faculty of Public Health, Ahvaz Jundishapur University of Medical Sciences Ahvaz, Iran. 6MSc of Anatomy, Shoushtar Faculty of Medical Sciences, Shoushtar, Iran.

ABSTRACT

BACKGROUND: In vitro, Ziziphus Spina-Christi (ZSC) leaves have been shown to have antimicrobial and antifungal effects. This study aimed to examine the effects of Ziziphus Spina leaves hydro-alcoholic extracts with Clotrimazole against Candida albicans in female rats.

METHODS: Four groups of rats were infected vaginally with C. Albicans, and 1 group not infected was considered negative control. The infected groups received the following treatments: 2 groups were treated with vaginal 5%, or 10%, of Ziziphus Spina extract creams. One group received 1% clotrimazole, and 1 group did not receive any treatment considered a positive control.

RESULTS: The mean number of colony-forming units (CFUs) before the intervention was 195.83 ± 395.126 in the 5% ZSC group, 346.33 ± 396.719 in the 10% ZSC group, 345.17 ± 507.431 in the clotrimazole group, 212.20 ± 148.304 in the positive control group (P = .003). After 1 week, the average number of CFUs considerably dropped to 65.14 ± 36.03 in the 5% ZSC group, 1.43 ± 3.60 in the 10% ZSC group, and 0.43 ± 1.13 in the clotrimazole group. The number in the positive control group remained unchanged (212.20 ± 148.304) (P = .005). After 2 weeks, the average number of CFUs was 0 in the 10% ZSC group, Clotrimazole and negative control groups, and was 4.57 ± 23.99 in the 5% ZSC group (P < .001).

CONCLUSIONS: Our findings indicated that the effectiveness of Vaginal creams containing 10% Ziziphus Spina is similar to Clotrimazole in eliminating C. Albicans.

KEYWORDS: Clotrimazole, Candida albicans, vaginal cream, Ziziphus

Introduction

Vulvovaginal candidiasis (VVC) is the second most common cause of infectious vaginitis. At least 75% of women have experienced VVC once in their life, and 5% more than 4 times a year. Typically, 90% of Candida albicans-related infections are harmless and asymptomatic. However, VVC infections may be associated with severe itching, vaginal soreness, pruritis, pain, irritation, unpleasant odor, dyspareunia, dysuria, and burning during micturition. Previous investigations revealed that in different provinces of Iran, the frequency of VVC varies from 4.8% to 73%. Although it is not a life-threatening condition, it can cause physical and psychological problems and deteriorate marital relationships. The limited number of effective antifungal drugs is an excellent issue in treating fungal infections. Many of these drugs have toxic effects, and since most of these drugs possess antifungal activities against fungi rather than killing fungal pathogens, they relapse in their treatment. Echinocandins, caspofungin, micafungin, anidulafungin, and fluconazole are some of the drugs used to treat vaginal candidiasis. Clotrimazole is a broad-spectrum drug mainly used to treat vaginal candidiasis and other fungal infections. Abdominal pain, diarrhea, headache, rash, indigestion, allergic reaction, and severe skin reaction are all possible adverse effects of antifungal drugs. On the other hand, long-time treatment with these drugs leads to acquired drug resistance. Treatment of this disease is complex due to contributing factors and the risk of recurrence. Some natural products, such as probiotic supplements, organic apple cider vinegar, and organic garlic, are commonly used to treat C. Albicans. The Rhamnaceae family’s Ziziphus Spina-Christi (L.) (ZSC) (Sider) is a tropical evergreen tree found mainly in the Sinai Peninsula. (Egypt). In other Middle Eastern countries, it is known as Nakba and...
Sird.11,12 ZSC is utilized for its antimicrobial and antifungal properties in traditional medicine.13-15 The leaves of ZSC are used to heal wounds, skin illnesses, inflammatory problems, sores, ringworm, fever, gonorrhea, sexually transmitted disease, and ulcers in Saudi Arabian traditional medicine.16,17 In Iranian traditional medicine, the leaves of ZSC are used as an antibacterial, antifungal, and anti-inflammatory agent and for treating skin illnesses, including atopic dermatitis.15,18,19 Metabolites such as flavonoids and alkaloids are the main antimicrobial agents which cause inhibition of bacteria growth. Detailed examination of ZSC showed that this plant contains flavonoids, alkaloids, saponins, lipids, proteins, and free sugar as the dominant chemical composition has antibacterial activity.2,14 Analysis activities related to the ZSC, its methanolic and ethanolic extract indicated the preventing growth effect on different species of Gram-negative bacteria.12,20 Treatment of C. Albicans with Barhi date extract induced cell wall deformation, weakness, and partial collapse, according to Shraideh et al.21 Cell lysis, cytoplasmic substance leakage, and cell death was detected at high doses. New antifungal tactics attempt to create drugs that combine lower manufacturing costs, high efficacy, local toxicity, and safety for humans, animals, host plants, and ecosystems. Furthermore, investigations have shown that ZSC leaves have antifungal properties.13-15

Objectives
There was insufficient data on the efficiency of ZSC leaf extract against Candida albicans. The goal of the present study was to compare the effects of ZSC leaves hydro-alcoholic extract and Clotrimazole on Candida albicans in Wistar rats.

Methods
Ethics statement
We conducted a double-blind, randomized, controlled study in female Wistar rats to examine ZSC leaves’ effects on hydro-alcoholic extract compared to Clotrimazole on C. Albicans. The Medical Sciences ethics committee approved this study (Ref. No.: IR.SHOUSHTAR.REC.1398.009).

Preparation of C. albicans suspension
Candida albicans was isolated from a Candida vaginitis patient. (According to the DNA Data Bank of Japan, C. Albicans Code of Standard: Atcc10231) Moreover, it is used to infect rats. At 28°C-30°C, yeast extract peptone dextrose (YEPD) medium was used for cell culture. The cells were washed 3 times with sterile phosphate-buffered saline after (PBS) 48 hours. The OD was measured for the preparation suspension of 1 × 108 cells/mL (1 × 107 cells in 100 μL).

Induction vaginitis in Wistar rats
Wistar rats (n = 50) weighing 150 to 200 g were randomly put into 5 groups (10 per group). For 1 week, each group was placed in a separate cage with a sterile straw under standard temperature and light (12 hour light-dark cycle, temperature 20°F-25°F, and humidity 50%-60%).22 To ensure the rats were not contaminated, the samples were cultured in 2 forms; with and without chloramphenicol. Candida albicans was cultured on a YEPD medium. After 18 hours, the cultured yeasts were washed 3 times with PBS. This mixture was centrifuged, and 5 × 107 to 1 × 108 yeast cells were suspended in PBS. Two estradiol valerate doses were injected subcutaneously in the lower abdomen during the first and third days to suppress the rats’ hormonal systems.9 After the second estradiol injection, 0.1 mL yeast suspension was injected into the vagina, and the rats were kept upside down for about 1 minute to ensure the inoculum.

Preparation of ZSC leaf extract
Fresh Iranian Z. Spina-Christi (sird) with green leaves were collected. Leaves were washed and then air-dried in the shade at 30°C ± 2°C for 4 days and then transferred to the pharmacognosy lab. The dried green sird leaves were pulverized, and a maceration procedure was used to make an extract. The powdered green sird was mixed with 80% ethanol and kept at room temperature (27°C-32°C) for 3 days, stirring occasionally. Using a vacuum flask, the mixture was filtered using Whatman paper. The extract was freeze-dried to a fine bulk powder after being dried in a vacuum rotary evaporator at 45°C. The powder was stored at a temperature of less than 4°C. The extract was added to a suitable cream basis (an emulsion of water in oil) at concentrations of 5% and 10% (w/w) to make ZSC leaves hydro-alcoholic extract.23 The same base was utilized at the pharmacy to manufacture 1% clotrimazole cream. All finished solutions had the same appearance, and an authorized color was utilized to assure consistency. The produced formulations were subjected to microbiological and physicochemical testing (uniformity, physical stability, distribution, and acidity). 5% and 10% ZSC leaves and clotrimazole creams were put in identical containers and coded A, B, and C by a blinded third party. The texture and appearance of all the creams were the same. Creams were administered, and a blinded researcher prepared samples.

Grouping
The rats were divided into 5 groups of 10 rats each:

1- C. Albicans-infected control group that was not treated (positive control)
2- An uninfected control group that was not treated (negative control)
3- An infected group underwent therapy with a hydro-alcoholic extract of 5% ZSC leaves.
4- An infected group underwent therapy with a 10% hydro-alcoholic extract of ZSC leaves.
5- An infected group underwent therapy with a 1% clotrimazole.
Assessment of infection

A vaginal sample was taken from each rat before commencing therapy (6 days after the initial injection of yeast suspension into the vagina of rats). To screen for bacterial infection, the samples were cultured on Sabouraud dextrose agar with chloramphenicol (SC). An additional yeast dosage was administered to the vagina if the infection was not discovered. According to references, the number of yeast colonies in a sample is usually assessed by criteria of 7 to 8 colonies per swab.\(^\text{24}\)

A colony counter machine counted the number of colonies growing on the plate surface, and the direct sample revealed more yeast colonies.

Intervention

After the rats’ infections, the case groups received 5% or 10% hydro-alcoholic ZSC extraction. The concentrations of ZSC extraction were chosen based on the previous study to find whether the increasing drug resistance of Candida Albicans over time is efficient.\(^\text{4}\)

Statistical analysis

Descriptive statistics, including mean and standard deviation (SD), were utilized to describe the fracture resistance values. The normality of data distribution was assessed using Shapiro-ilk and Kolmogorov Smirnov tests. Data analysis was performed using Kruskal-Wallis and post hoc tests. The significant level was considered as \(P < .05\). The collected data were analyzed with IBM.SPSS statistics software 24.0 Version.

Results

Before the intervention, all samples were evaluated for confirmation of CFUs accumulation (Figure1A0, B0, C0, D0). 1 week later, the mean number of CFUs significantly reduced (P-Value = .005) in 3 groups, including 5% ZSC group (65.14 ± 36.03), 10% ZSC group (1.43 ± 3.60), and clotrimazole group (0.43 ± 1.13) (Figure1A1, B1, C1, D1) (Table 1).

After 2 weeks, the mean number of CFUs was 0 in both the 10% ZSC leaves group and Clotrimazole and negative control groups and 4.57 ± 23.99 in the 5% ZSC leaves group (\(P < .001\)) (Figure1A2, B2, C2, D2) (Table 1).

Discussion

Despite the existence of various treatments for opportunistic infections, nevertheless, the refractory to treatments for these pathogens are increasing, such as Candida albicans. The drug resistance against Candida albicans in vulnerable patients such as diabetic and cancerous patients is a critical concern.\(^\text{25,26}\) This issue causes a proliferation of studies intending to recognize the new therapeutic agents with the lowest side effects.\(^\text{27}\)

Despite considerable evidence in this field, still, there are inconsistent results due to influencing factors such as type of herbal, concentration, and used methods.\(^\text{22}\) Additionally, following the recognized mechanism of drug-refractory of candida Albicans, it was understood that the traditional treatments are becoming outdated.\(^\text{28}\) In this regard, the present survey aims to investigate the efficacy of ZSC hydro-alcoholic extraction in growth inhibition of Candida albicans compared with standard treatment by Clotrimazole. Our data revealed that the 10% concentration of ZSC hydro-alcoholic extraction had the highest therapeutic efficacy, the same with Clotrimazole.

Numerous studies have attempted to improve therapeutic strategies against prevalent infections, such as Candida albicans, to reduce treatments’ side effects. The common inhibitory mechanisms of herbal agents with synthetic drugs in infection restriction cause the proliferation of studies in this field. Previous investigations report the most antifungal of Lawsonia inermis, Pelargonium graveolens, Camellia sinensis, Mentha piperita, and Citrus latifolia against Candida albicans;\(^\text{29}\) whereas our findings indicated the 10% of Zizyphus Spina leaves’ hydro-alcoholic extract has favorable outcome as the same with Clotrimazole. Following our results, Lashin et al\(^\text{30}\) have shown that Zinc and selenium oxide nanoparticles biosynthesized using callus extract of ZSC have potential antimicrobial activity and antioxidant activity.

### Table 1. Results before and after treatment in groups.

| GROUPS | BEFORE INTERVENTION | 1 WEEK AFTER THE INTERVENTION | 2 WEEK AFTER THE INTERVENTION | \(P\)-VALUE* |
|--------|---------------------|-------------------------------|-------------------------------|-------------|
| A      | 195.83 ± 395.126    | 65.14 ± 36.03                | 4.57 ± 23.99                  | .001       |
| B      | 345.17 ± 507.431    | 0.43 ± 1.13                  | 0.00 ± 0.000                  |            |
| C      | 346.33 ± 396.719    | 1.43 ± 3.60                  | 0.00 ± 0.000                  |            |
| D      | 212.20 ± 148.304    | 178.00 ± 173.551             | 174.80 ± 164.970              |            |
| P**    | .604                | .005                          | >.001                         |            |

A, 5% of Zizyphus Spina leaves extract group; B, 1% clotrimazole group; C, 10% of Zizyphus Spina leaves extracts group; D, positive control group; E, negative control group.

*Group and time interaction in the GEE model.

**P-value between groups.
Similar to our aim, the results of Soliman et al\textsuperscript{31} demonstrated that Saussurea costus Root extracts have a therapeutic effect in Candida albicans treatment. Additionally, it was shown that herbal products are more efficient in treating drug-resistant candida sp.\textsuperscript{32}

For Candida albicans growth inhibition, critical mechanisms for surviving Candida albicans must be targeted; including inhibition of hyphae transformation, biofilm formation, cell wall or cytoplasmic membrane biosynthesis, ROS production, and over-expression of membrane transporters.\textsuperscript{32} Zizyphus Spina containing saponin disrupts the cell wall of Candida albicans.\textsuperscript{33} Additionally, Zizyphus Spina has endophytic A. Alternaria, which has potent antioxidant activity that can cause cell membrane disruption.\textsuperscript{34} Finally, the tannins in Zizyphus Spina, by eliminating Iron, reduce the pathogen growth and proliferation.\textsuperscript{35}

Figure 1. (A): 5% of Zizyphus Spina leaves extracts group, (B): 1% clotrimazole group, (C): 10% of Zizyphus Spina leaves extracts group, (D): positive control group. 0: before the intervention, 1: 1 week after intervention, 2: 2 weeks after intervention.
In a study by Butassi et al., it was reported that Phytolaccata tetramerata from Argentina has antifungal activity against Candida albicans and Candida glabrata. After examination of 12 Phytolaccata tetramerata extracts, they found that dichloromethane extract from berries, by altering the plasma membrane, has the most effective therapeutic activity.

Conversely, Mardani et al. compared Lawsonia inermis and ZSC Christi by nystatin and fluconazole, inhibiting Candida activity from liver transplant patients. Their findings indicated that ZSC Christi unripe fruit and L. inermis leaf have potential anti-Candida activity.

Understanding the mechanism of ZSC in drug-resistance candida Albicans inhibition can improve our knowledge in promoting the efficacy of the therapeutic effect of ZSC. The main limitation of the present survey is no measurement of various concentrations of ZSC against both sensitive and resistant candida Albicans. Since vulnerable patients are the main concern for fungal infection, drug interaction should be considered in these patients. In this regard, further clinical trials to evaluate the efficacy of ZSC in candida Albicans treatment are highly recommended in vulnerable patients.

**Conclusion**

The results of our study indicated that with increasing drug-refractory of candida Albicans, extraction of ZSC can be helpful in candida Albicans restriction. Recently, it was demonstrated that nanobiotechnology had shown the beneficial effect of improving herbal products’ efficacy in infection treatment. Hence, it is highly recommended that more investigations consider this issue.

**Acknowledgements**

We wish to thank all our colleagues in Allied Health Sciences School, Shoushtar and Jundishapur University of medical sciences.

**Authors’ Contributions**

Azam Honarmandpour and Amir Masoud Keshavarzzade were involved in the study design. Azam Honarmandpour, Hossein Kamali, Mahnaz Fatahinia and Amir Masoud Keshavarzzade were involved in data collection. Azam Honarmandpour and Foroogh Namjayan were responsible for drug development. Elham Maraghi and Azam Honarmandpour were responsible for data interpretation. Azam Honarmandpour was responsible for writing and finalizing manuscript in English.

**Availability of Data and Materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Ethics Approval and Consent to Participate**

The Medical Sciences ethics committee approved this study (Ref. No.: IR.SHOUSHTAR.REC.1398.009). All methods were performed in accordance with the relevant guidelines and regulations the study is reported in accordance with ARRIVE guidelines.

**REFERENCES**

1. Ahmad A, Khan AU. Prevalence of Candida species and potential risk factors for vulvovaginal candidiasis in Aligarh, India. Eur J Obstet Gynecol Reprod Biol. 2009;144:68-71.

2. Espinel-Ingroff A, Canton E, Benamouzig S, Forberg AW. Comparison of 24-hour and 48-hour voriconazole MICs as determined by the clinical and Laboratory Standards Institute Broth Microdilution Method (M27-A3 document) in three laboratories: results obtained with 2,162 clinical isolates of Candida spp. and other yeasts. J Clin Microbiol. 2009;47:2766-2771.

3. Bachhler YG, Parvavale VB. Microemulsion-based vaginal gel of clotrimazole: formulation, in vitro evaluation, and stability studies. AAPS PharmSciTech. 2009;10:476-481.

4. Abedi P, Yaralizadeh M, Fatahinia M, Najmianvand-Chegini S, Yaralizadeh M. Comparison of the effects of lugnaga green husk and clotrimazole on candida albicans in rats. Jundishapur J Microbiol. 2017:11:e58151.

5. Chandr-GT, Goniis-S, Karapinar-M. Efficacy of myrtle oil against Salmonella Typhimurium on fresh produce. Int J Food Microbiol. 2009;130:147-150.

6. Cribby S, Taylor-M, Reid-G. Vaginal microbiota and the use of probiotics. Interdiscip Perspect Infect Dis. 2008;2008:256-260.

7. Samani S, Forooumani A, Falahati M, et al. 2-Hydroxyphenacyl azoles and related azolium derivatives as antifungal agents. Biorg Med Chem Lett. 2008;18:141-146.

8. Wu HH, Chen YT, Shih CJ, Lee YT, Kuo SC, Chen TL. Association between recent use of proton pump inhibitors and nonsteroi dals: a nested case-control study. Clin Infect Dis. 2014;59:1554-1558.

9. Pavlova SI, Tao L. In vitro inhibition of commercial douche products against vaginal microflora. Infect Dis Obstet Gynecol. 2000;8:99-104.

10. Bahadoran P, Rokni PK, Fahami F. Investigating the therapeutic effect of vagi nal cream containing garlic and thyme compared to clotrimazole cream for the treatment of vaginal mycotic vaginitis. Iran J Nurses Midwifery Res. 2010;15:343-349.

11. Michel CG, Nessem DI, Ismail MF. Anti-diabetic activity and stability study of the formulated leaf extract of Ziziphus spina-christi (L.) Willd with the influence of seasonal variation. J Ethnopharmacol. 2011;133:53-62.

12. Kadioglu O, Jacob S, Bohnh eit S, et al. Evaluating ancient Egyptian prescriptions today: anti-inflam matory activity of Ziziphus spina-christi. Phyto medicine. 2016;23:293-306.

13. Bahmani M, Avijian M, Ghasemi Pirbalouti A, Bahmani M. Anti-candida activity of some of the Iranian medicinal plants. Electr J Biol. 2009;5:85-88.

14. Agarpanah J. Phytochemistry and pharmacologic properties of Ziziphus spina christi (L.) Willd. AJP J Pharm Pharmacol. 2012;6:2312-2339.

15. Dikhl MA, Al-Qa rashiya S, Moreini EA. Ziziphus spina-christi leaf extract pretreatment inhibits liver and spleen injury in a mouse model of sepsis via antioxid ant and anti-inflammatory effects. Inflammopharmacology. 2018;26:779-791.

16. Vent N, Duane J, A. A & Ayesous, E. S., Medicinal Plants of Chena. 2 Feb. 705 S., 1300 Strichzeichnungen. Reference Publ., Inc. Algonac. Michigan, 1985. ISBN 0-917266-20-4. Preis. gb. m. Schutzumschlag $49.95. J Bot Taxon Geobot. 1987;98:399-398.

17. Adi EN, Rajendrasozhan S, Hassan SI, Sherif MS, Sharawy S, Humaidi JR. Phytochemical, antimicrobial and cytotoxic | Biomedical Research. Biomed Res. 2017;28:66-64.

18. Abalaka ME, Danyi SY, Manno A. Evaluation of the antimicrobial activities of two Ziziphus species (Ziziphus mauritiana L. and Ziziphus spinaciahristi L.) on some microbial pathogens. Afr J Pharm Pharmacol. 2010;4:135-139.

19. Orhan DD, Ozcelik B, Ozgen S, Ergun F. Antibacterial, antifungal, and antiviral activities of some flavonoids. Inflammopharmacology. 2010;2008:256490.

20. Abru una MA, Ahmad S, Nwosu E., Ziziphus juubylon Leaf pretreatment inhibits liver transplant patients. Zizyphus extract on fungal infection. Iran J Pharm Res. 2010;0:81-81.

21. Shutahay A, Al-Awadi A, Al-Ameen A. Ultrastructural effects of date extract on Candida albicans in rats. Jundishapur J Microbiol. 2017;28:65-70.

22. Gonzalez-Burgos E, Gomez-Serranillos MP. Natural products for vulvovaginal candidiasis treatment: evidence from clinical trials. Curr Top Med Chem. 2010;10:141-146.

23. Banks ET, Lancaster H. Oral manifestations of systemic disease. Dermatol Clin. 2003;21:171-182.

24. d’Enfert C, Kaune AK, Alaban LR, et al. The impact of the fungus-host-microbiota interplay upon Candida albicans infections: current knowledge and new perspectives. FEMS Microbiol Rev. 2021;45:fuaa060.
26. Unnikrishnan A, Kalra S, Purandare V, Vasanwalla H. Genital infections with sodium glucose cotransporter-2 inhibitors: occurrence and management in patients with type 2 diabetes mellitus. *Indian J Endocrinol Metab.* 2018; 22:837.

27. Rosseto LRB, Martelli EC, da Silva JC, et al. Susceptibility of Candida albicans strains isolated from vaginal secretion in front of the mycocins of Wickerhamomyces anomalus. *Probiotics?Antimicrob?Proteins.* 2022;14:595-601.

28. Padder SA, Ramzan A, Tahir I, Rehman RU, Shah AH. Metabolic flexibility and extensive adaptability governing multiple drug resistance and enhanced virulence in Candida albicans. *Critical Reviews in Microbiology.* 2022;48: 1-20.

29. Hsu H, Sheth CC, Veses V. Herbal extracts with antifungal activity against Candida albicans: a systematic review. *Mini Rev Med Chem.* 2021;21:90-117.

30. Iashin I, Hasanin M, Hassan SAM, Hashem AH. Green biosynthesis of zinc and selenium oxide nanoparticles using callus extract of Ziziphus spina-christi: characterization, antimicrobial, and antioxidant activity. *Biomass Convers Biorefinery.* 2021;11:1-14.

31. Soliman MF, Shetaia YM, Tayel AA, et al. Exploring the antifungal activity and action of Saussurea costus Root extracts against Candida albicans and non-albicans species. *Antibiotics.* 2022;11:327.

32. Herman A, Herman AP. Herbal products and their active constituents used alone and in combination with antifungal drugs against drug-resistant Candida sp. *Antibiotics.* 2021;10:655.

33. Nazemoroozay Z, Sarafshiraz M, Mahdieh A, Zeini D, Nyström B. Use of saponinsomes from Ziziphus spina-christi as anticancer drug carriers. *ACS Omega.* 2022;7:28421-28433.

34. Elghaffar RYA, Amin BH, Hashem AH, Sehim AE. Promising endophytic *Alternaria alternata* from leaves of *Ziziphus spina-christi*: phytochemical analyses, antimicrobial and antioxidant activities. *Appl Biochem Biotechnol.* 2022; 194:3984-4001.

35. El Maaiden E, El Kharrassi Y, Moustaid K, Essamadi AK, Nasser B. Comparative study of phytochemical profile between *Ziziphus spina christi* and *Ziziphus lotus* from Morocco. *J Food Meas Charact.* 2019;13:121-130.

36. Butassi E, Svetaz LA, Zhou S, et al. The antifungal activity and mechanisms of action of quantified extracts from berries, leaves and roots of *Phytolacca tetramera.* *Phytomedicine.* 2019;60:152884.

37. Badiee P, Mardani M, Gharibnavaz M, Jassebi A, Jafarian H, Ghassemi F. Comparison of anti-Candida activities of the ancient plants *Lawsonia inermis* and *Ziziphus spina christi* with antifungal drugs in Candida species isolated from oral cavity. *J Conserv Dent.* 2018;21:359.